Expansion momentum Polpharma is actively expanding internationally, with new offices in India and Southern Asia and recent platform launches in Poland for RNA-based medicines. This indicates growing global sourcing, manufacturing partnerships, and API supply chain opportunities for collaboration, contract manufacturing, and technology transfers.

Strategic acquisitions The acquisition of Biofarm SA for €270 million signals a capacity and market reach expansion in Europe, suggesting potential cross-sell of capabilities, integration services, and combined product portfolios for distributors, contract manufacturing, and generic drug pipelines.

RNA and platform play Launching an RNA-based medicines platform in Starogard Gdański points to a focus on advanced therapeutics and high-value manufacturing—areas where collaboration with CROs, CMOs, and tech-enabled drug development partners could yield joint ventures and service contracts.

Leadership and growth A leadership transition with a new President signals strategic renewal and potential emphasis on international expansion, efficiency improvements, and diversified manufacturing networks, presenting opportunities for executive outreach, partnerships, and channel development.

Employer credibility Polpharma’s recognition as a great place to work and its status as a leading regional generic producer enhances its attractiveness to global suppliers, partners, and distributors, enabling smoother negotiation, co-branding, and collaborative programs with stability signals.